Sequana Medical - Edison Group

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Sparks
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

YXT.com

MCap

USD127m

Last close

USD23.43

▲ 20.23 (632.19%)

Northern Data Group

MCap

EUR486m

Last close

EUR7.56

▲ 2.33 (44.59%)

Bodycote

MCap

GBP1,572m

Last close

GBP9.23

▲ 173.00 (23.07%)
Sectors
Sectors
Megatrends
Megatrends
- Artificial intelligence
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
Corporates

Investors

Careers

“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”

Edison Client
Equity Research
Investor Relations
Contact us

Sequana Medical (BRU: SEQUA)

Last close As at 05/08/2026

—

— 0.00 (0.00%)

Market capitalisation

—

Overview
Research
Thematics

Latest Insights

View More

Healthcare |
edison tv

26.01.24

Sequana Medical – executive interview

Healthcare |
Flash note

05.01.24

Sequana Medical — New CPT III codes to support reimbursement

Healthcare |
Flash note

03.01.24

Sequana Medical — PMA application submitted to FDA for alfapump

Healthcare |
Flash note

04.12.23

Sequana Medical — Positive data in non-randomised MOJAVE cohort

Close up of Doctor is showing medical analytics data of Coronavirus (Covid-19), Medical technology concept

Market Data

Share Price —

Market Cap —

52-Week High —

52-Week Low —

% Change 1M

% Change 6M —

% Change 12M

Ave. Daily Volume 1yr —

Sector

Healthcare

Flash note

Healthcare

18.11.22

Sequana Medical — SAHARA results pave the way for DSR 2.0

edison tv

Healthcare

15.11.22

Sequana Medical – Executive Interview

Update

Healthcare

03.11.22

Sequana Medical — POSEIDON results de-risk alfapump programme

Flash note

25.10.22

Sequana Medical — POSEIDON pivotal study meets primary endpoint

Update

Healthcare

12.09.22

Sequana Medical — Approaching key inflection points

research

Healthcare

15.08.22

Sequana Medical — DSR 2.0 moving forward

Flash note

Healthcare

19.07.22

Sequana Medical — A step closer on DSR heart failure programme

Update

Healthcare

27.04.22

Sequana Medical — Guidance maintained for key programmes

Update

Healthcare

08.04.22

Sequana Medical — Completion of POSEIDON study implantations

Update

Healthcare

15.12.21

Sequana Medical — DSR reduces congestion in heart failure

Flash note

Healthcare

06.12.21

Sequana Medical — POSEIDON enrolment completed on schedule

Update

Healthcare

07.10.21

Sequana Medical — FDA clears expansion of POSEIDON enrolment

Update

Healthcare

10.09.21

Sequana Medical — Pushing back alfapump PMA to mid-2023

edison tv

Healthcare

28.07.21

Sequana Medical – executive interview

Update

Healthcare

07.07.21

Sequana Medical — Efficacy maintained in second interim analysis